Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2045

Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.

Patents
1,566

Quick answer

1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12209116

    Recombinant human C1 esterase inhibitor and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12208099

    Combination therapies

    Mirati Therapeutics, Inc. · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12209138

    Anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 2025034260

    FCRN ANTAGONISTS FOR TREATMENT OF IGG-RELATED DISEASES AND DISORDERS

    ABLYNX NV [BE] · Granted Thu Jan 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 2025034157

    PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

    ABBVIE INC [US] · Granted Thu Jan 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2025023851

    ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE

    BIAL PORTELA & CA SA [PT] · Granted Thu Jan 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2025023852

    ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE

    BIAL PORTELA & CA SA [PT] · Granted Thu Jan 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12213977

    Methods and compositions for treating melanoma

    The Regents of the University of California · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12213951

    Treatment of autism with cannabidiol

    Harmony Biosciences Management, Inc. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12215169

    Anti-complement C1s antibodies and uses thereof

    Bioverativ USA Inc. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12215316

    Materials and methods for treatment of usher syndrome type 2A

    CRISPR THERAPEUTICS AG · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12213973

    Bacterial nitric oxide synthase inhibitors

    Northwestern University · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12213989

    Use of maribavir in treatment regimens

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12215108

    Development of potential antidotes for arsenicals

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12213990

    A3 adenosine receptor ligand for use for achieving a fat loss effect

    CAN-FITE BIOPHARMA LTD. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12214218

    Perfusion modulated tumor dose sculpting with single dose radiotherapy

    FUNDAçÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12215060

    Performance of technical ceramics

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12215133

    GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use

    BrightGene Bio-Medical Technology Co., Ltd. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12215135

    PDL2 compounds

    IO Biotech ApS · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12215343

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12215349

    Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12215093

    Bicyclic carboxamides and methods of use thereof

    TEMPEST THERAPEUTICS, INC. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12213941

    Adapter for use in a planetary mixer

    MEDISCA PHARMACEUTIQUE INC. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12214015

    Use of c-type natriuretic peptide variants to treat osteoarthritis

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12215105

    HPK1 antagonists and uses thereof

    Nimbus Saturn, Inc. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12214002

    Compositions and methods for treating antibiotic resistance

    Seres Therapeutics, Inc. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12219327

    Substituted isoindolines as PI3K-alpha inhibitors

    Relay Therapeutics, Inc. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12215321

    Modulators of diacyglycerol acyltransferase 2 (DGAT2)

    Ionis Pharmaceuticals, Inc. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12213964

    Isoxazoline parasiticide formulations

    Tarsus Pharmaceuticals, Inc. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12213985

    Oral cannabinoid formulations

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12213998

    Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12214076

    Drug delivery vehicles for atherosclerosis nanomedicine

    Northwestern University · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12215322

    Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12214021

    Study on lactoferrin regulation of bone formation by means of vitamin D receptor

    China Agricultural University · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12215320

    Compositions and methods for gene editing by targeting transferrin

    CRISPR THERAPEUTICS AG · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12214023

    Compositions and methods for expressing factor IX

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12214019

    Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins

    Rani Therapeutics, LLC · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12213996

    Methods of treating optic nerve diseases using neural progenitor cell growth factors

    REGENERATIVE RESEARCH FOUNDATION · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12214045

    Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods

    Nektar Therapeutics · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12215347

    Chimeric antigen receptors with enhanced signaling and activities and uses thereof

    Allogene Therapeutics, Inc. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12215148

    Antigen binding molecule formats

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12215090

    Agents and methods for treating dysproliferative diseases

    Tri-Institutional Therapeutics Discovery Institute, Inc. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12214083

    Pharmaceutical composition and administrations thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12215164

    Immunotoxins with albumin binding domain

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12214031

    Mannheimia haemolytica vector

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12215138

    Compositions and methods for internalizing enzymes

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12215131

    IgG Fc-IL2-Rα-IL2 fusions and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12214061

    Adhesive composition for dental use

    KURARAY NORITAKE DENTAL INC. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2045?

1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.